乳腺癌筛查范式的演变:平衡有效性、个性化与公平性
乳腺癌仍是全球重大健康挑战,预计发病率将上升。筛查项目被赞为拯救生命之举,但对死亡率真实影响仍有争议,并存在假阳性与惰性肿瘤检出导致过度治疗的风险。领先时间、病程长度与选择偏倚使筛查效果评估复杂化。近期研究提示AI驱动图像分析可能革新乳腺癌筛查,在保持诊断准确性的同时减轻放射科医生工作量,但结论向多样人群的外推需重点考量。个性化筛查与先进技术的公平可及对缩小差距至关重要。筛查格局正演变,强调风险分层、合适影像方式与个性化路径以减少过度诊断并聚焦可能影响生命的癌症,同时优先以患者为中心的照护。
要点
- AI驱动图像分析可能革新乳腺癌筛查,在保持诊断准确性的同时减轻放射科医生工作量。
- 筛查存在假阳性与惰性肿瘤检出导致过度治疗的风险。
- 领先时间、病程长度与选择偏倚使筛查效果评估复杂化。
核心结论
- 乳腺癌筛查格局正演变,强调风险分层、合适影像方式与个性化路径以减少过度诊断,聚焦可能影响生命的癌症,并优先以患者为中心的照护。
研究设计与样本
- 综述;检索范围与纳入文献原文未报告。
临床应用与阅片要点
- AI驱动图像分析可能革新乳腺癌筛查,在保持诊断准确性的同时减轻放射科医生工作量,但结论向多样人群的外推需重点考量。
- 个性化筛查与先进技术的公平可及对缩小差距至关重要。
- 筛查需权衡假阳性与惰性肿瘤检出导致过度治疗的风险。
- 评估筛查效果时需考虑领先时间、病程长度与选择偏倚。
局限性
- 筛查对死亡率真实影响仍有争议。
- 筛查存在假阳性与惰性肿瘤检出导致过度治疗的风险。
- 领先时间、病程长度与选择偏倚使筛查效果评估复杂化。
- AI研究结论向多样人群的外推需重点考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Breast cancer remains a significant global health challenge, with projections indicating a troubling increase in incidence. Breast cancer screening programs have long been hailed as life-saving initiatives, yet their true impact on mortality rates is a subject of ongoing debate. Screening poses the risk of false positives and the detection of indolent tumors, potentially leading to overtreatment. Bias factors, including lead time, length time, and selection biases, further complicate the assessment of screening efficacy. Recent studies suggest that AI-driven image analysis may revolutionize breast cancer screening, maintaining diagnostic accuracy while reducing radiologists' workload. However, the generalizability of these findings to diverse populations is a critical consideration. Personalized screening approaches and equitable access to advanced technologies are essential to mitigate disparities. In conclusion, the breast cancer screening landscape is evolving, emphasizing the need for risk stratification, appropriate imaging modalities, and a personalized approach to reduce overdiagnosis and focus on cancers with the potential to impact lives while prioritizing patient-centered care.
引用
- Pesapane F, Rotili A, Raimondi S, et al. Evolving paradigms in breast cancer screening: Balancing efficacy, personalization, and equity. Eur J Radiol. 2024. PMID: 38244317. doi:10.1016/j.ejrad.2024.111321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。